Pharmafile Logo

Article: Market access in Brazil

All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient’s health.

In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

Read more on this article here: https://bit.ly/2qZ5HW1

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Review of Disease Promotion Campaign using Facial Analysis

Our client had developed a visual and emotion-invoking, online disease awareness campaign aimed at challenging physicians’ current perceptions of treatment. Research was required to understand physicians’ reactions to the campaign...

Emotional Recognition using Facial Analysis

Do you have a poker face or does your expression give you away?  According to psychologists, a lot of emotional information can be drawn from our facial expressions, which is...

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

20 questions: Round 7

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What project or event has been most memorable to you at RP?"Watch...

Innovation, sustainability and prosperity: Japan’s healthcare vision for the future

The vision for Japan 2035; A healthcare system that delivers unrivalled health outcomes, providing secure and responsive care for all members of society, sustainable, and contributing to prosperity in the...

Tools to action your segmentation

Our tools for ensuring a successful segmentation rollout

Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report

Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers  in the US. The report will consist of 45-minute quantitative and 30-minute qualitative interviews with AD...

The value of design thinking: Incorporating creative and graphic design into pharma market research

How do we keep research design fresh and interesting? How do we ensure that we’re inspiring our respondents to give us enlightening new insights, and encourage new ways of thinking?There...

Research Partnership launches new patient Living with Psoriasis 2017 (EU) report

Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased...

Deep Dive – MINT: opportunities in ‘frontier’ markets?

According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are...